只有 BRCA 基因突变的患者才应该接受雄激素受体通路抑制剂和 PARP 抑制剂联合治疗转移性阉割耐药前列腺癌吗？答案是否定的。

IF 4.8 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2024-08-17 DOI:10.1016/j.euf.2024.07.015

Fred Saad

引用次数: 0

摘要

从雄激素受体通路抑制剂和 PARP 抑制剂联合治疗中获益最多的患者是那些 BRCA 基因突变的患者，但当然也有一些没有 BRCA 基因突变的患者会从这种治疗策略中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No.

Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.